PureTech Health (NASDAQ:PRTC) Stock Price Up 9%

PureTech Health plc (NASDAQ:PRTC) shares traded up 9% during mid-day trading on Monday . The company traded as high as $22.20 and last traded at $22.20. 4,777 shares were traded during trading, an increase of 56% from the average session volume of 3,062 shares. The stock had previously closed at $20.36.

Analysts Set New Price Targets

PRTC has been the topic of several research analyst reports. Leerink Partners initiated coverage on shares of PureTech Health in a research report on Monday. They issued an “outperform” rating and a $45.00 price objective on the stock. Leerink Partnrs raised shares of PureTech Health to a “strong-buy” rating in a report on Monday.

PureTech Health Stock Performance

The company has a 50 day simple moving average of $22.32 and a 200-day simple moving average of $25.72.

Institutional Trading of PureTech Health

A hedge fund recently bought a new stake in PureTech Health stock. AWM Investment Company Inc. acquired a new position in PureTech Health plc (NASDAQ:PRTC) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,900 shares of the company’s stock, valued at approximately $197,000. 0.04% of the stock is owned by hedge funds and other institutional investors.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.